1	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Household
2	Transmission during the Omicron Era in Massachusetts: A Prospective, Case-Ascertained
3	Study using Genomic Epidemiology
4	
5	Jaspreet Banga <sup>1</sup> *, Taylor Brock-Fisher <sup>2,3</sup> *, Brittany A. Petros <sup>2,4</sup> *, Eric Y. Dai <sup>5</sup> , Ariana T.
6	Leonelli <sup>5</sup> , Sabrina T. Dobbins <sup>2</sup> , Katelyn S. Messer <sup>2</sup> , Audrey B. Nathanson <sup>5</sup> , Amelia Capone <sup>6</sup> ,
7	Nancy Littlehale <sup>6</sup> , Viola Appiah-Danquah <sup>5</sup> , Siang Dim <sup>5</sup> , Gage K. Moreno <sup>2</sup> , Maura Crowther <sup>5</sup> ,
8	Kannon A. Lee <sup>5</sup> , Katherine C. DeRuff <sup>2</sup> , Bronwyn L. MacInnis <sup>2</sup> , Michael Springer <sup>7</sup> , Pardis C.
9	Sabeti <sup>2,3,8,9</sup> , Kathryn E. Stephenson <sup>1,5,10,11,#</sup>
10	
11	*These authors contributed equally.
12	
13	<sup>1</sup> Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, MA, USA
14	<sup>2</sup> The Broad Institute of MIT and Harvard, Cambridge, MA, USA
15	<sup>3</sup> Department of Organismic and Evolutionary Biology, Faculty of Arts and Sciences, Harvard
16	University, Cambridge, MA, USA
17	<sup>4</sup> Harvard/MIT MD-PhD Program, Boston, MA, USA
18	<sup>5</sup> Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA,
19	USA
20	<sup>6</sup> Beth Israel Lahey Health Primary Care, Chelsea, MA, USA
21	<sup>7</sup> Department of Systems Biology, Harvard Medical School, Boston, MA, USA
22	<sup>8</sup> Harvard T.H. Chan School of Public Health, Boston, MA, USA
23	<sup>9</sup> Howard Hughes Medical Institute, Chevy Chase, MD, USA

- <sup>24</sup> <sup>10</sup>Harvard Medical School, Boston, MA, USA
- <sup>25</sup> <sup>11</sup>Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of
- 26 Technology (MIT) and Harvard, Cambridge, MA, USA
- 27
- 28 #Corresponding Author: Kathryn E. Stephenson, MD, MPH, Center for Virology and Vaccine
- 29 Research, Beth Israel Deaconess Medical Center, E/CLS-1037, 300 Brookline Ave, Boston, MA
- 30 02215. Email: kstephen@bidmc.harvard.edu.
- 31
- 32 Key Points: When community transmission of SARS-CoV-2 is high, distinguishing household

33 transmissions from independent introductions is difficult with either epidemiologic or genomic

34 data alone. Here, we conducted daily nasal sampling with genomic sequencing to understand the

35 dynamics of viral transmission within households.

36

38	Abstract:
----	-----------

39

40 <u>Background:</u>

41 Households are a major setting for SARS-CoV-2 infections, but there remains a lack of

42 knowledge regarding the dynamics of viral transmission, particularly in the setting of widespread

43 pre-existing SARS-CoV-2 immunity and evolving variants.

44

45 <u>Methods:</u>

We conducted a prospective, case-ascertained household transmission study in the greater
Boston area in March-July 2022. Anterior nasal swabs, along with clinical and demographic
data, were collected for 14 days. Nasal swabs were tested for SARS-CoV-2 by PCR. Whole
genome sequencing was performed on high-titer samples.

50

51 <u>Results</u>:

52 We enrolled 33 households in a primary analysis set, with a median age of participants of 25 53 years old (range 2-66); 98% of whom had received at least 2 doses of a COVID-19 vaccine. 54 58% of households had a secondary case during follow up and the secondary attack rate (SAR) 55 for contacts infected was 39%. We further examined a strict analysis set of 21 households that 56 had only 1 PCR+ case at baseline, finding an SAR of 22.5%. Genomic epidemiology further 57 determined that there were multiple sources of infection for household contacts, including the 58 index case and outside introductions. When limiting estimates to only highly probable 59 transmissions given epidemiologic and genomic data, the SAR was 18.4%.

## 61 <u>Conclusions:</u>

- 62 Household contacts of a person newly diagnosed with COVID-19 are at high risk for SARS-
- 63 CoV-2 infection in the following 2 weeks. This is, however, not only due to infection from the
- 64 household index case, but also because the presence of an infected household member implies
- 65 increased SARS-CoV-2 community transmission. Further studies to understand and mitigate
- 66 household transmission are needed.

67

# **INTRODUCTION**

71	In March 2022, the SARS-CoV-2 Omicron variant BA.2 and its descendants caused multiple
72	outbreaks across the greater Boston area of Massachusetts <sup>1</sup> . More than 95% of the population of
73	Massachusetts at that time had received at least one dose of a COVID-19 vaccine, and a large
74	number of individuals had been infected with the Omicron BA.1 variant only a few months
75	prior <sup>1</sup> . Despite this presence of partial population immunity, there were over 200,000 new
76	COVID-19 cases reported in Massachusetts between March and July 2022, coincident with the
77	dropping of mask requirements and a reduction in social distancing policies.
78	
79	Throughout the COVID-19 pandemic, households have been a major setting for SARS-CoV-2
80	transmission <sup>2</sup> . A meta-analysis of 135 studies published in 2022 found that the secondary attack
81	rate (SAR) – the risk of transmission from index case to household contact – of exposed
82	household contacts was 30-36% during the Alpha and Delta SARS-CoV-2 waves and 43%
83	during the early (BA.1) Omicron period <sup>2</sup> . Factors associated with transmission risk were the
84	vaccine status of the exposed contact, household density (i.e., the number of people sleeping in
85	the same room), and immunological factors such as the magnitude of cross-reactive memory T
86	cells to SARS-CoV-2 antigens <sup>3-5</sup> . In general, the SARs reported in households, and other
87	residential settings <sup>6</sup> , have been far higher than reported in other settings such as schools, where a
88	SAR of 2.8% was reported for exposed students in 10 Massachusetts schools during the Delta
89	wave <sup>7</sup> .

91	Despite the large number and range of household studies performed to date, there remains a lack
92	of precision and detail regarding the dynamics of SARS-CoV-2 household transmission. These
93	studies are each individually small in size, and most lack careful characterization on the genomic
94	level. This uncertainty is particularly important in the increasingly common scenario where there
95	is (1) widespread pre-existing SARS-CoV-2 immunity, either from vaccination or infection, (2)
96	emergence of new SARS-CoV-2 strains that are partially immune evasive, and (3) few infection
97	control precautions in home and community environments. Knowing the risk of household
98	transmission in this scenario, as well as identifying factors that can predict lower SARs, would
99	enhance our ability to counsel patients appropriately and meaningfully reduce SARS-CoV-2
100	infections in households.
101	
102	To address this research gap, we conducted a household SARS-CoV-2 transmission study in the
103	greater Boston area in March-July 2022 in which we used clinical, demographic, viral kinetic,
104	and genomic data for high-resolution analyses of SARS-CoV-2 transmission dynamics.
105	
106	METHODS:
107	
108	We conducted a prospective, observational, case-ascertained transmission study of household
109	contacts of index SARS-CoV-2 cases identified in the greater Boston and Chelsea areas of
110	Massachusetts in the United States. The primary recruitment pathway was via ambulatory
111	COVID-19 testing sites associated with Beth Israel Deaconess Medical Center (BIDMC).
112	
113	

#### 114 Ethics

115 The BIDMC Committee on Clinical Investigation, its Institutional Review Board (IRB), 116 approved the study protocol (#2022P000021). Consent procedures were completed via 117 phone/video conferencing or in-person. All enrolled participants provided verbal informed 118 consent. Participants who met applicable IRB guidelines for provision of assent underwent an 119 age-appropriate assent process; informed consent for study participation was obtained from each 120 participant's parent or legal guardian before any study-specific procedures were performed. 121 Sequencing of SARS-CoV-2-positive specimens was covered under protocol #1612793224, 122 reviewed and approved by the Massachusetts Institute of Technology (MIT) IRB. 123 124 **Study Population** 125 An index case was eligible for inclusion if the participant (1) had a positive SARS-CoV-2 test 126 either by rapid diagnostic assay or RT-PCR no more than 5 days prior to enrollment and had no 127 more than 5 days of acute respiratory illness symptoms prior to testing, and (2) lived, and had 128 plans to live in his/her household for the follow-up period of 14 days, and (3) was not 129 hospitalized and had not been hospitalized since the date of illness onset, and (4) was at least 2 130 years old. An index case was excluded from the study if the participant did not live in a 131 household (e.g., lived alone or in a congregate setting), or if they reported that any other person 132 in the household had an acute respiratory illness or tested positive for SARS-CoV-2 in the 7 days 133 before the test date or illness onset date of the index case. 134 135 A household contact was eligible for inclusion if the participant (1) routinely slept (at least half

136 of the nights in the last month) in the same household as the index case, and (2) slept in the

household at least once between 1 day prior to the earliest of the index case's illness onset or
positive test date and (3) had plans to live in the household for the follow-up period, and (4) was
at least 2 years old.

140

## 141 **Respiratory Specimen Collection**

142 Each enrolled index case and household member self-collected an anterior nasal swab

143 (Rhinostics dry swab in a sterile tube; <u>https://rhinostics.com/</u>) on each day of the 14-day follow-

144 up period. The swab was self-collected regardless of whether the individual had acute respiratory

145 illness signs or symptoms. Samples were dropped off by the participants at the BIDMC Clinical

146 Research Center or the Chelsea clinic. A subset of participants who were treated with

147 nirmatrelvir-ritonavir were asked to extend the follow-up period and continue self-swabbing for

148 an additional 7 days in order to monitor for potential virologic rebound<sup>8</sup>.

149

### 150 **Questionnaires**

151 At enrollment, each consenting household member and index case, or his/her parent/guardian,

152 was asked to provide information on participant demographics, recent exposures to COVID-19,

153 presence of high-risk conditions, prior and current symptoms of COVID-19, COVID-19

154 vaccination status, household characteristics, interactions with other enrolled and non-enrolled

155 household members and people outside the home, and other social or medical history, including

156 other vaccination history, as deemed appropriate. An optional follow-up questionnaire was

administered to participants on days 7 and 14.

158

### 160 SARS-CoV-2 Viral Load Quantification

161 Viral loads were measured with the Quaeris SARS-CoV-2 Assay, a real-time reverse

- 162 transcription polymerase chain reaction (rRT-PCR) test, using the Luna Probe One-Step RT-
- 163 qPCR Kit (No ROX) [NEB E3007]<sup>9</sup>. The SARS-CoV-2 primer and probe set detects RNA from
- 164 the SARS-CoV-2 N1 and RdRP genes, and uses the human RNase P gene as a positive control.
- 165 When received by the laboratory, samples were rehydrated with 300 µl phosphate buffered saline
- 166 (PBS), inactivated at 65°C, and subsequently used directly as input for the Quaeris assay without
- 167 extraction. rRT-PCR was performed on an Applied Biosystem QuantStudio 7 instrument
- 168 (software version 1.7). Liquid handling was automated using either the Tecan Fluent 1080, the
- 169 Hamilton Star, or the Multidrop combi dispenser. N1 gene cycle threshold (Ct) values are

170 reported. Viral rebound was defined as at least 2 negative (Ct≥35) PCR results followed by at least

171 2 positive (Ct<35) results.

172

## 173 SARS-CoV-2 Whole Genome Sequencing

Anterior nasal swabs that were positive for SARS-CoV-2 with Ct values of maximally 32 via the
Quaris assay were sequenced as previously described<sup>10</sup>. Briefly, following inactivation with
Buffer AVL, RNA was extracted from the samples using the MagMAX mirVana Total RNA
Isolation Kit for the Kingfisher Flex (Thermo Fisher #A27828) according to the manufacturer's
instructions. The ARTIC v4.1 primer set was used to amplify SARS-CoV-2 genetic material,
from which Illumina DNA Prep sequencing libraries were prepared and sequenced on the
NextSeq 550<sup>11</sup>.

181

#### 183 SARS-CoV-2 Genomic Data Analysis

184 Sequencing reads were demultiplexed, filtered to remove adapter and contaminant sequences, 185 depleted of reads mapping to the human genome, and assembled by alignment to the reference 186 sequence NC045512.2 via the viral-ngs v2.1.33 pipeline<sup>12</sup>. The following optional inputs were 187 used with the assemble refbased workflow to accommodate amplicon-based sequencing: 188 major cutoff = 0.5, min coverage = 20, skip mark dupes = TRUE, and trim coords bed = 189 "gs://pathogen-public-dbs/v1/amplicon\_primers-ARTICv4.1\_NC\_045512.2.bed". 190 Lineages were assigned to viral genomes using Pango v4.1.3 pango-data v1.17<sup>13</sup>. Consensus 191 192 single nucleotide variants (SNVs) were determined after removing ambiguous sites and sites 193 prone to amplicon sequencing error<sup>14</sup>. Intrahost single nucleotide variants (iSNVs) were called 194 using LoFreq and were filtered as follows: (i) masking of known problematic sites in SARS-195 CoV-2 genome, (ii) site read depth of minimally 100; (iii) allele frequency of minimally 3%; and (iv) no evidence of strand bias (via Fisher's exact test with p > 0.05)<sup>11,15</sup>. 196

197

### 198 Transmission Analysis

To infer the relatedness of cases within a household, the most complete genome (i.e., the genome with the highest percentage of unambiguous sites) was used for each person with a minimum unambiguous genome length of 15,000 bp. The genetic (SNV) distance between pairs of cases was used alongside the serial interval, viral kinetics, iSNV information, and test status of other individuals at baseline to classify households into transmission categories. All pairs of cases within each household were assessed, excluding those inconsistent with the longitudinal testing data.

206 Transmissions were categorized as highly probable, possible, or unlikely. Pairs with a genetic 207 distance of less than 2 SNVs and an iSNV in a putative donor that reached consensus in the putative 208 recipient (i.e., transmission of a minor variant through a tight transmission bottleneck) were considered highly probable<sup>16,17</sup>. An index-contact pair in the strict analysis set (i.e., from a 209 210 household with a single infected participant and documented PCR- contacts at baseline) with a 211 genetic distance of less than 3 SNVs and a serial interval of less than 7 days were also considered 212 highly probable transmissions. Pairs with a genetic distance of less than 3 SNVs and a serial 213 interval of less than 7 days, but without iSNV support, were categorized as a possible transmission, though we cannot rule out a non-household recent common ancestor (i.e., a shared exposure)<sup>18,19</sup>. 214 215 Pairs with a genetic distance of 3 or more SNVs or a serial interval of minimally 7 days were considered unlikely. Highly probable and possible transmission links were plotted.<sup>20,21</sup> 216

217

### 218 **Phylogenetic Analysis**

Contextual genomes (10 BA.1 sequences each from Massachusetts and the United States, and 50 BA.2 sequences each from Massachusetts and the United States, isolated between 2022-02-01 and 2022-08-01) were downloaded from NCBI GenBank. These sequences, along with the most complete genome assembled per study participant (of minimally 15,000 bp), were aligned to the reference sequence (NC\_045512.2) using Nextclade v.2.14.1<sup>22</sup>. A phylogenetic tree was estimated using IQ-TREE v.2.2.2.6<sup>23</sup> and was visualized and annotated using ggtree v.3.8.2<sup>24</sup> in R v.4.3.1.

225

### 227 **RESULTS**

228

### 229 Screening, Enrollment, and Follow-up

Enrollment began on March 3, 2022 and continued until July 9, 2022, after local SARS-CoV-2

case counts had declined<sup>1</sup>. We enrolled 38 households containing 38 index cases and 77

household contacts; Figure 1. One household was subsequently found to be ineligible and 4

households did not complete 14 days of follow up. The remaining 33 households (33 index cases

and 66 household contacts) constituted our primary analysis set; 85% of these households

235 (28/33) had all household members participate. Of the 33 households in the primary analysis set,

236 3 households had an index case that was PCR- at the time of first research swab, and 9

237 households had at least one household contact that were PCR+ at the time of first research swab.

238 The remaining 21 households (21 index cases and 40 PCR- household contacts) constituted our

strict analysis set. The median number of persons per household in the primary analysis set was

240 3.5 (range, 2-5; <u>Supplementary Table 2</u>). The median house size was 1400 square feet (range,

241 740-3300; <u>Supplementary Table 2</u>).

242

#### 243 Study Population

Demographic and clinical characteristics of index cases and household contacts in the primary
analysis set are shown in <u>Table 1</u> and <u>Supplemental Table 1</u>. The median age was 25 years
(range, 5-64) for index cases and 39 years (range, 2-66) for household contacts. 23% of
participants were children in elementary or middle school. Participants were predominantly
White and Non-Hispanic. 81% of participants reported having no medical conditions. The most
common reported medical conditions were asthma (12%), autoimmune or immune system

disease (8%), and high blood pressure (4%). 10% of participants reported having COVID-19 at

some point prior to the study (though symptom- and testing-based ascertainment bias is likely).

252 98% of participants received at least 2 vaccine doses. The median duration between most recent

253 vaccination or most recent infection was 160 days (range 0-307).

254

#### 255 SARS-CoV-2 Infections

Of the 33 households in the primary analysis set, 19 (58%) had a household contact who tested positive by PCR during follow up (Figure 2A and Table 2). Of the 66 household contacts in the primary analysis set, 26 tested positive, indicating a putative SAR of 39%; 11 of these cases were detected on day 1 of swabbing. If limiting analysis to the 21 households in the strict analysis set, 9 (43%) households had a new incident infection during follow up, corresponding to 9 infections out of 40 household contacts, or a putative SAR of 22.5%.

262

263 In the primary analysis set of 33 households, the median minimal Ct - corresponding to peak 264 viral load - was 25.65 for index cases and 23 for infected household contacts (Supplemental 265 Table 3). Median duration of viral shedding was 6.5 days and 8 days for index cases and 266 contacts, respectively, and the median time to positive SARS-CoV-2 test from index diagnosis 267 date was 3 days. The lower viral load and decreased duration of shedding for index cases is most 268 likely due to the fact that cases were detected partway through infection. Eleven participants 269 reported taking nirmatrelvir-ritonavir; 3 participants had viral rebound (Supplemental Figure 1A: 270 MPO-02, BQE-01 and BQE-02)<sup>8</sup>.

271

### 273 SARS-CoV-2 Sequencing

274 For the primary analysis set, approximately 1300 total anterior nasal swab samples were 275 collected and analyzed via the rRT-PCR Quaris assay. 181 of these samples, from 48 unique 276 individuals across 26 unique households, had a diagnostic Ct under 32 (mean = 30.1) and were 277 thus subject to genomic sequencing. 178/181 (98.3%) samples had a nonzero unambiguous 278 assembly length with a median length of 29,321bp. 143 samples, which came from 44 unique 279 individuals among 24 unique households, produced partial genomes of at least 15,000 bp in 280 length (Supplemental Table 4). 15 households yielded partial genomes from multiple individuals 281 within the household. The vast majority of the sequences were BA.2 descendants, consistent with 282 national trends (Figure 2B), though a BA.1 sequence was collected early in enrollment. 283 284 Focusing first on analyzable households in the strict analysis set (N=6), we found that four 285 households had viral sequences that were either identical between index and secondary cases or 286 differed by only 1-2 SNVs (Figure 3A, Supplemental Table 5). In these cases, transmission from 287 index to secondary case was considered highly probable. In two households, we identified 288 significant viral variation between sequences isolated from the index and secondary contacts, 289 strongly suggesting that the secondary cases were independent introductions (Figure 3B). In 290 household XOA, the index case was infected with a BA.2.13 variant, while the contact was 291 infected with BA.2.12.1; there was a 13 SNV difference between sequences. In household 292 WMD, the index case was infected with BA.2.12.1, and the contact was infected with BA.2; 293 there was a 20 SNV difference between sequences. (Of the 3 remaining households with 294 secondary cases in the strict analysis set (AXB, JDU and NKF), sequences were not available or 295 couldn't be analyzed; viral kinetic curves for these households are in Figure 3C). When

excluding the 2 household contacts that were infected outside of the household, the SAR among
individual household contacts in the strict analysis set was 18.4% (<u>Table 2</u>).

298

299 Analyzing transmission networks among all the households in the primary analysis set revealed 300 several interesting patterns. In 5 households, there were clusters of infections (2-3 per household) 301 that were all genetically linked to the index case (Figure 4A (a representative example), and 302 Supplemental Figure 1A). In these households, there were 0 SNVs different between index and 303 contact sequences, but the close overlap in diagnosis dates suggests that either a shared common 304 exposure or intra-household transmission was possible. In 3 households, there were two distinct 305 clusters of infections detected (Figure 4B (a representative example), and Supplemental Figure 306 1B). In these households, the index case was infected with a virus that was 3-4 SNVs different 307 than the viruses that circulated in the rest of the household. In 1 household (Figure 4C), there 308 was evidence that the index case was co-infected with 2 contemporaneously circulating strains 309 (BA.2.1.12 and BA.2.10) while the contact was infected with solely BA.2.1.12; given the close 310 diagnosis dates, this could be explained by either a shared social network or transmission with a 311 bottleneck.

312

### 313 **Potential Predictors of Transmission**

To explore potential predictors of transmission between an index case and household contact, we examined the 7 household contacts where transmission from the index was highly likely compared to the 28 participating contacts that remained uninfected. Using Wilcoxon rank sum and Fisher's exact tests (<u>Table 3</u>), we found that there was no association between infection status and the contact's prior COVID-19 vaccination, number of prior vaccines received, history of prior infection, days since vaccination and/or infection, age or sex assigned at birth. There was
also no association between infection status and the associated index case's prior COVID-19
vaccine status, minimum Ct value, or duration of SARS-CoV-2 shedding, and no association
between infection status and the number of persons in the household or and square footage. The
small sample size and homogeneity of many of these variables (e.g., vaccine history) limited the
power of our analysis to detect predictors of transmission risk.

325

### 326 **DISCUSSION**

327

328 Here we studied the transmission dynamics of SARS-CoV-2 within households using 329 prospective daily PCR surveillance, clinical and demographic data, and genomic epidemiology. 330 Our study is well-positioned to reflect the transmission dynamics of households consisting of 331 relatively young, healthy individuals with pre-existing immunity to SARS-CoV-2. It was 332 conducted during a wave of Omicron BA.2 and its sub-lineages. Our study population consisted 333 primarily of families with 2-5 members; 23% of our participants were children in elementary or 334 middle school. Participants were highly vaccinated, having received a median of 3 COVID-19 335 vaccines. Only 10% had a known prior COVID-19 diagnosis and the population was overall very 336 healthy.

337

Our study found that the risk of SARS-CoV-2 in exposed households is very high, consistent with previous reports. In our primary analysis set, we found that 58% of enrolled households went on to have a second SARS-CoV-2 case in the household over the next 2 weeks. Nearly a third of households had a positive secondary case identified on the very first day of testing. At

the individual level, we found that 39% of household contacts tested positive for SARS-CoV-2
during follow up. Following the infection of a household contact, putatively negative household
members must make decisions around travel and attending school or work. Here, we provide
data that could inform this value-based decision.

346

347 We further aimed to more rigorously estimate the risk of SARS-CoV-2 transmission directly 348 from an index case, performing a strict analysis including only households that had one 349 confirmed PCR+ index case and only PCR- household contacts at the beginning of surveillance. 350 In this analysis, we identified 9 cases among 40 household contacts, or a SAR of 22.5%. Using 351 genomic epidemiology, we then excluded 2 cases as these were likely acquired outside of the 352 household. We thus determined that SAR was 18.4%. Our study was conducted when multiple 353 BA.2 descendants were circulating, and this genetic diversity improved our ability to rule out 354 putative transmission events.

355

356 Using genomic epidemiology across all the households, we found that the infectious source of 357 secondary cases was varied. The most common source of infection was the index case, but other sources included an imported case (outside the household), shared exposures with the index, or 358 359 other infected contacts within the home. Our findings, particularly evidence of shared exposures 360 and imported cases, highlight that infection within a household serves as a proxy for broader risk 361 for community transmission, emphasizing the importance of maintaining vigilant public health 362 measures both inside and outside of the home. More public health attention should be focused on 363 mitigating this risk via vaccination and therapeutic advances, enhanced and early case detection 364 and isolation, and non-pharmaceutical interventions such as masking and ventilation.

366	SAR estimates have varied considerably across multiple studies, due to varying study designs,
367	populations, and circulating SARS-CoV-2 variants. During the Alpha and Delta waves, the SAR
368	for exposed household contacts was reported between 30-36%, rising to 43% during the early
369	(BA.1) Omicron period <sup>2</sup> . Here we report that during a BA.2 wave (and its descendants), the SAR
370	was 39% using a larger primary set of households, 22.5% with a strict set of households, and
371	18.4% when further incorporating genomic data. This lower estimate using genomic data is
372	likely a more accurate reflection of the true risk of household exposure.
373	
374	Our small sample size substantially limited our power to assess predictors of transmission,
375	especially because prior COVID-19 vaccination was near universal in our study cohort. Given
376	the complexity of estimating the magnitude of pre-existing SARS-CoV-2 immunity by history
377	alone, particularly in the context of both infection and prior vaccines, future household
378	transmission studies would benefit from larger cohorts and baseline immunologic assessments of
379	humoral, cellular and mucosal immune responses.
380	
381	In summary, we determined that the risk of household transmission of SARS-CoV-2 is very
382	high, even when using genomic epidemiology to exclude imported cases. Further interventions to
383	block household transmission should be studied, especially in the now-common scenario when
384	population immunity and vaccine coverage are high but viral variants are increasingly immune
385	evasive.
386	
387	

388 Acknowledgements

- 389 We thank the participants and staff at the Center for Virology and Vaccine Research Clinical
- 390 Trials Unit, the Harvard Catalyst Clinical Research Center, and the Beth Israel Deaconess
- 391 Primary Care—Chelsea Clinic. We also thank Daniel J. Park for providing important feedback
- 392 on the manuscript, and Janet Morgan for administrative support.
- 393

## 394 **Funding Sources**

- 395 This study was supported by the Massachusetts Consortium for Pathogen Readiness (K.E.S.),
- 396 Beth Israel Deaconess Medical Center (K.E.S.), National Institutes of Health (R01-GM120122 to
- 397 M.S.), Harvard Catalyst, the National Institute of General Medical Sciences (T32GM007753 and
- 398 T32GM144273 to B.A.P.), the Centers for Disease Control and Prevention (CDC) COVID-19
- 399 baseline genomic surveillance contract to the Clinical Research Sequencing Platform
- 400 (75D30121C10501 to B.L.M.), a CDC Broad Agency Announcement (75D30120C09605 to
- 401 B.L.M.), the CDC Pathogen Genomic Centers of Excellence (NU50CK000629 to B.L.M and
- 402 P.C.S), the National Institute of Allergy and Infectious Diseases (U19AI110818 and

403 U01AI151812 to P.C.S.), and Howard Hughes Medical Institute (P.C.S.).

404

## 405 Conflicts of Interest

406 P.C.S. is a co-founder of, shareholder in, and scientific advisor to Sherlock Biosciences, Inc and

- 407 Delve Bio; she is also a Board member of and shareholder in Danaher Corporation. P.C.S. has
- 408 filed IP related to genome sequencing and analysis. The authors declare no other conflicts of
- 409 interests.
- 410

411	FIGU	JRE I	LEGEI	NDS

412

413	Figure	1.	Trial	profile.
<del>т</del> 15	riguit	1.	11141	prome.

414

415	Figure 2. Household diagram. (A) Individual households are labeled with a 3-letter identifier
416	and represented with grey boxes. Households in both the primary and strict analysis sets are
417	shown. Each member of the household is shown within the grey box, with their outcome color-
418	coded as described in the legend. (B) Phylogenetic map of positive samples.
419	
420	Figure 3. Viral load curves and transmission plots by household in the strict analysis set.
421	(A) Households where transmission was determined to be highly probable are shown. (B)
422	Households where transmission was determined to be unlikely are shown. (C) Households that
423	did not yield sufficient sequencing data are shown.
424	
425	Figure 4. Representative viral load curves and transmission plots from primary analysis
426	set. (A) A representative household is shown where either a shared exposure (i.e., social
427	network) exists or within-household transmission has occurred, as all cases are genetically linked
428	to the index case. (B) A representative household is shown where two separate infection clusters
429	were identified. (C) A household is shown where a putative co-infection was identified in the
430	index case.
431	
432	Supplemental Figure 1. Additional viral load curves and transmission plots by household in

433 the primary analysis set. Households are shown where either a shared exposure exists or

- 434 possible transmission has occurred, as all cases are genetically linked to the index case.
- 435 Households are shown where two separate infection clusters were identified.

436

## 438 **References**:

- 439 1. Massachusetts Department of Public Health COVID-19 Dashboard, <u>www.mass.gov</u>.
- 440 2. Madewell ZJ, Yang Y, Longini IM, Jr., Halloran ME, Dean NE. Household Secondary
- 441 Attack Rates of SARS-CoV-2 by Variant and Vaccination Status: An Updated Systematic
- 442 Review and Meta-analysis. JAMA Netw Open. Apr 1 2022;5(4):e229317.
- 443 doi:10.1001/jamanetworkopen.2022.9317
- 3. Singanayagam A, Hakki S, Dunning J, et al. Community transmission and viral load
- kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals
  in the UK: a prospective, longitudinal, cohort study. *Lancet Infect Dis*. Feb 2022;22(2):183-195.
- 446 In the UK: a prospective, longitudinal, conort study. *Lancet Infect Dis.* Feb 2022;2 447 doi:10.1016/S1473-3099(21)00648-4
- 448 4. Kleynhans J, Walaza S, Martinson NA, et al. Household Transmission of Severe Acute
- 449 Respiratory Syndrome Coronavirus 2 From Adult Index Cases With and Without Human
- 450 Immunodeficiency Virus in South Africa, 2020-2021: A Case-Ascertained, Prospective,
- 451 Observational Household Transmission Study. *Clin Infect Dis*. Feb 8 2023;76(3):e71-e81.
  452 doi:10.1093/cid/ciac640
- 453 5. Kundu R, Narean JS, Wang L, et al. Cross-reactive memory T cells associate with
  454 protection against SARS-CoV-2 infection in COVID-19 contacts. *Nat Commun.* Jan 10
  455 2022;13(1):80. doi:10.1038/s41467-021-27674-x
- 456 6. Petros BA, Turcinovic J, Welch NL, et al. Early Introduction and Rise of the Omicron
- 457 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant in Highly 458 Vaccineted University Depulations, *Clin Infect Dis*, Ech. 8 2022;76(2)):e400, e408
- 458 Vaccinated University Populations. *Clin Infect Dis*. Feb 8 2023;76(3):e400-e408.
  459 doi:10.1093/cid/ciac413
- 460 7. Nelson SB, Dugdale CM, Brenner IR, et al. Prevalence and Risk Factors for School461 Associated Transmission of SARS-CoV-2. *JAMA Health Forum*. Aug 4 2023;4(8):e232310.
- 462 doi:10.1001/jamahealthforum.2023.2310
- 463 8. Dai EY LK, Nathanson AB, Leonelli AT, Petros BA, Brock-Fisher T, Dobbins ST,
- 464 MacInnis BL, Capone A, Littlehale N, Boucau J, Marino C, Barczak AK, Sabeti PC, Springer M,
- 465 Stephenson KE. Viral Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
- 466 CoV-2) Omicron Infection in mRNA-Vaccinated Individuals Treated and Not Treated with 467 Nirmatrelvir-Ritonavir. medRxiv [Preprint]. *medRxiv* 2022011322269257. 2022;
- 468 9. Emergency Use Authorization (EUA) Summary Quaeris SARS-CoV-2 Assay. *Available* 469 *at: <u>https://wwwfdagov/media/149445/download</u>. 2021;*
- 470 10. Petros BA, Paull JS, Tomkins-Tinch CH, et al. Multimodal surveillance of SARS-CoV-2
- 471 at a university enables development of a robust outbreak response framework. *Med.* Dec 9
  472 2022;3(12):883-900 e13. doi:10.1016/j.medj.2022.09.003
- 473 11. <u>https://github.com/artic-network/artic-ncov2019/tree/master/primer\_schemes/nCoV-</u>
  474 2019/V4.1.
- 475 12. Park, D et al., <u>https://github.com/broadinstitute/viral-ngs/tree/v1.25.0</u>.
- 476 13. O'Toole A, Scher E, Underwood A, et al. Assignment of epidemiological lineages in an 477 emerging pandemic using the pangolin tool. *Virus Evol*. 2021;7(2):veab064.
- 478 doi:10.1093/ve/veab064
- 479 14. https://github.com/W-L/ProblematicSites\_SARS-
- 480 <u>CoV2/blob/master/problematic\_sites\_sarsCov2.vcf.</u>

- 481 15. Wilm A, Aw PP, Bertrand D, et al. LoFreq: a sequence-quality aware, ultra-sensitive
- 482 variant caller for uncovering cell-population heterogeneity from high-throughput sequencing
  483 datasets. *Nucleic Acids Res.* Dec 2012;40(22):11189-201. doi:10.1093/nar/gks918
- Braun KM, Moreno GK, Wagner C, et al. Acute SARS-CoV-2 infections harbor limited
  within-host diversity and transmit via tight transmission bottlenecks. *PLoS Pathog*. Aug
  2021;17(8):e1009849. doi:10.1371/journal.ppat.1009849
- 487 17. Song JS, Lee J, Kim M, et al. Serial Intervals and Household Transmission of SARS-
- 488 CoV-2 Omicron Variant, South Korea, 2021. *Emerg Infect Dis*. Mar 2022;28(3):756-759.
- 489 doi:10.3201/eid2803.212607
- 490 18. Bendall EE, Callear AP, Getz A, et al. Rapid transmission and tight bottlenecks constrain
- the evolution of highly transmissible SARS-CoV-2 variants. *Nat Commun.* Jan 17
- 492 2023;14(1):272. doi:10.1038/s41467-023-36001-5
- 493 19. Lythgoe KA, Hall M, Ferretti L, et al. SARS-CoV-2 within-host diversity and
  494 transmission. *Science*. Apr 16 2021;372(6539)doi:10.1126/science.abg0821
- 495 20. Campbell F, Cori A, Ferguson N, Jombart T. Bayesian inference of transmission chains
- 496 using timing of symptoms, pathogen genomes and contact data. *PLoS Comput Biol*. Mar
- 497 2019;15(3):e1006930. doi:10.1371/journal.pcbi.1006930
- 498 21. Jombart T, Cori A, Didelot X, Cauchemez S, Fraser C, Ferguson N. Bayesian
- 499 reconstruction of disease outbreaks by combining epidemiologic and genomic data. *PLoS*
- 500 *Comput Biol.* Jan 2014;10(1):e1003457. doi:10.1371/journal.pcbi.1003457
- Aksamentov I, Roemer C, Hodcroft EB, Neher RA. Nextclade: clade assignment,
   mutation calling and quality control for viral genomes. *The Journal of Open Source Software*.
- 503 2021;6(67)
- 504 23. Nguyen LT, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: a fast and effective
- stochastic algorithm for estimating maximum-likelihood phylogenies. *Mol Biol Evol.* Jan
  2015;32(1):268-74. doi:10.1093/molbev/msu300
- 507 24. Yu G, Smith DK, Zhu H, Guan Y, Tsan-Yuk Lam T. ggtree : an r package for
- 508 visualization and annotation of phylogenetic trees with their covariates and other associated data.
- 509 *Methods in Ecology and Evolution*. 2016;
- 510

# TABLES

# Table 1.Baseline Characteristics of Study Population

Characteristic	All Participants (N=99)	Index Cases (N=33)	Contacts (N=66)	
Age (Median, Min-Max)	27 (2-66)	25 (5-64)	39 (2-66)	
Sex assigned at birth (N, %) –				
Male	44 (48.4)	14 (43.8)	30 (50.9)	
Female	47 (51.7)	18 (56.3)	29 (49.2)	
Missing	8	1	7	
<b>Race</b> (N, %) –				
American Indian or Alaskan Native	10 (11.0)	3 (9.4)	7 (11.9)	
Asian	2 (2.2)	1 (3.1)	1 (1.7)	
Black or African American	0	0	0	
Native Hawaiian or Other Pacific Islander	0	0	0	
White	79 (86.8)	28 (87.5)	51 (86.4)	
Multiple	0	0	0	
Prefer Not to Report	0	0	0	
Other	0	0	0	
Missing	8	1	7	
Ethnicity (N, %) –				
Hispanic or Latino / Latinx	3 (3.3)	1 (3.1)	2 (3.4)	

Not Hispanic or Latino / Latinx	88 (96.7)	31 (96.9)	57 (96.6)
Missing	8	1	7
Body Mass Index (Median, Min/Max)	22.9 (14.1-7.2)	23.0 (16.1- 37.1)	22.7 (14.1- 47.2)
Missing	19	9	10
Medical Conditions (N, %)			
None	69 (81.2)	21 (72.4)	48 (85.7)
Cancer	0	0	0
Diabetes	1 (1.2)	1 (3.5)	0
Asthma or wheezing	10 (11.8)	5 (17.2)	5 (8.9)
COPD/Emphysema	0	0	0
High blood pressure	3 (3.5)	1 (3.5)	2 (3.6)
Coronary artery disease	0	0	0
Congestive heart failure	0	0	0
Peripheral artery disease	0	0	0
Other*	2 (2.4)	1 (3.5)	1 (1.8)
Missing	14	4	10
Autoimmune or Immune System Diseases, Any** (N, %)	7 (8.2)	1 (3.7)	6 (10.3)
Missing	14	6	8
Prior Diagnosis of COVID-19 (N, %)	9 (9.5)	1 (3.2)	8 (12.5)
Missing	4	2	2

Days between most recent diagnosis and enrollment (Median, Min- Max)	59 (18-780)	780	57 (18-462)
Hospitalized for COVID-19 (N, %) – missing 1	0	0	0
Prior Receipt of a COVID-19 Vaccine (N, %) – missing 2	95 (97.9)	32 (100)	63 (96.9)
Number of doses (Median, Min-Max)	3 (2-4)	3 (2-4)	3 (2-4)
Days between most recent COVID-19 vaccination and enrollment (Median, Min-Max) – <i>missing 4</i>	165 (1-308)	165 (48-308)	165 (1-307)
Days between most recent diagnosis OR most recent COVID-19 vaccination (whichever is more recent) and enrollment (Median, Min- Max)	160 (0-308)	164.5 (0-308)	160 (1-307)
Missing	2	1	1

\*Reported by participant: "heart aneurysm" (1); history of stroke (2) \*\*Reported by participant: "irritable bowel syndrome, eczema and allergies" (1); "vitiligo" (1); "diverticulosis" (1); "Reynaud's disease" (1)

# Table 2.SARS-CoV-2 Secondary Attack Rates

	# Events	Total Households	Total Contacts	<b>SAR (%)</b>
Primary Analysis Set				
Households with 2° cases	19	33	-	57.6
Individual 2º cases	26	-	66	39.4
Strict Analysis Set				
Households with 2° cases	9	21	-	42.9
Households with 2º cases, excluding households with outside infection	7	19	-	36.8
Individual 2º cases	9	-	40	22.5
Individual 2º cases, excluding individuals with outside infection	7	-	38	18.4

Table 3.Household Contact Characteristics by Infection Status (Strict Analysis Set), Excluding 2<sup>0</sup> Cases with OutsideInfections

	Infected Contact (N=7)	Not Infected Contact (N=28)	p-value
Characteristic of Household Contact			
Age (Median, Min-Max)	46 (13-50)	28.5 (10-64)	0.76 <sup>a</sup>
Male sex assigned at birth (N, %) Missing	2 (33.3) 1	13 (59.1%) 6	0.37 <sup>b</sup>
Number of COVID-19 vaccines received (Median, Min-Max) Missing	3 (2-3) 0	3 (2-4) 1	1.00 <sup>b</sup>
Days from last infection/vaccination (Median, Min-Max) Missing	146 (119-193) 0	138 (-1-197) 6	0.45 <sup>a</sup>
Characteristic of Associated Index Case			
Lowest Ct value (Median, Min-Max)	27.8 (18.2-35)	25 (15.9-33.9)	0.19 <sup>a</sup>
Duration of shedding in days (Median, Min-Max) Missing	7 (3-9) 0	8 (1-15) 0	0.41 <sup>a</sup>
Characteristic of Associated Household			
Number of persons in household (Median, Min-Max) Missing	4 (2-4) 0	4 (2-4) 1	0.10 <sup>b</sup>
Square footage (Median, Min-Max) Missing	1140 (740-3300) 2	1000 (740-3300) 15	0.59 <sup>a</sup>
<ul><li>a. Wilcoxon rank sum test</li><li>b. Fisher's Exact</li></ul>	•	•	

# SUPPLEMENTAL TABLES

# Supplemental Table 1. Additional Baseline Data

Characteristic	All Participants (N=99)	Index Cases (N=33)	Contacts (N=66)	
Currently Working / Employment (N, %) – missing 13				
Yes	57 (66.3)	18 (69.2)	39 (65.0)	
No	29 (33.7)	8 (30.8)	21 (35.0)	
Missing	13	7	6	
Student (N, %) – missing 9				
Yes	32 (35.6)	13 (43.3)	19 (31.7)	
No	58 (64.4)	17 (56.7)	41 (68.3)	
Missing	9	3	6	
If yes (N=32), level (N, %)				
Elementary	11 (34.4)	5 (38.5)	6 (31.6)	
Middle School	12 (37.5)	5 (38.5)	7 (36.8)	
High School	5 (15.6)	2 (15.4)	3 (15.8)	
Community College	0	0	0	
College or University	4 (12.5)	1 (7.7)	3 (15.8)	
Currently Uses eCigarettes/Vape (N, %) – missing 9	1 (1.1)	0	1 (1.6)	
Currently Smokes Cigarettes (N, %) – missing 9	1 (1.1)	0	1 (1.6)	

History of Smoking Cigarettes (N, %) – missing 10	11 (12.4)	3 (10.3)	8 (13.3)
If yes, packs per day (N, %)			
0.5	7 (63.6)	1 (33.3)	6 (75.0)
1.0	4 (36.4)	2 (66.7)	2 (25.0)
1.5	0	0	0
2.0	0	0	0
2.5	0	0	0
3 or more	0	0	0
If yes, how many years (N, %)			
1-5	8 (72.7)	2 (66.7)	6 (75.0)
5-10	0	0	0
10-15	1 (9.1)	0	1 (12.5)
15-20	0	0	0
20 or more	2 (18.2)	1 (33.3)	1 (12.5)
Concurrent Use of Steroids or Immune Suppressing Medications (N, %) – <i>missing 12</i>	6 (6.9)	1 (3.6)	5 (8.5)
Concurrent use of NSAIDs – missing 13	38 (44.2)	10 (37.0)	28 (47.5)

# Supplemental Table 2.Baseline Characteristics of Study Households in Primary Analysis Set

Characteristic	Total Households (N=33)
Number of persons in household (Median, Min-Max)	3.5 (2-5)
House size (in square feet) as reported by index (Median, Min-Max)	1400 (740-3300)
Missing or unknown data from 11 households	

# Supplemental Table 3. SARS-CoV-2 Viral Kinetics in Primary Analysis Set, Excluding 2 Cases of Outside Introduction

Outcome	Index Cases (N=30) <sup>a</sup>	Infected Contacts (N=26)
Lowest Ct (median, min-max)	25.65 (15.9-35)	23 (8.1-36.2)
Duration of viral shedding <sup>b</sup> (median, min-max)	6.5 days (1-19)	8 days (1-20)
Time to first positive SARS-CoV-2 from index diagnosis date	N/A	3 days (0-10)

a. Excluding 3 index cases who were PCR negative at baseline.

b. From first positive SARS-CoV-2 test.

# Supplemental Table 4. Sequencing Performance


Household	Participant	Samples	Samples Producing Genome with Minimum Unambiguous Genome Length of 15 kbp
AXB	1	1	0
	2	6	5
JRP	1	5	5
	2	6	6
ODK	1	1	1
EGI	1	6	6
	4	5	4
CWA	1	4	3
	2	4	3
VBL	1	1	1
TSE	1	1	1
	2	6	5
KQX	1	1	1
DUC	1	2	1
	2	8	7
MPO	2	5	4
	3	9	7
	4	4	3
HXJ	1	4	1
	3	5	5
BQE	1	7	5
	2	5	5
SVW	1	1	1


IRG	1	2	2	
	2	6	6	
	3	4	3	
	4	8	5	
LCT	1	7	5	
	4	11	9	
	5	9	9	
PFK	1	1	1	
	4	2	1	
JDU	1	1	1	
XOA	1	6	1	
	2	4	4	
REZ	1	1	0	
WMD	1	2	1	
	3	4	3	
HSA	1	1	1	
	2	5	3	
YVB	1	1	0	
NKF	1	1	1	
	2	1	0	
QEC	1	1	1	
OXS	1	2	2	
	2	1	1	
	4	2	2	
LME	1	1	1	

# Supplemental Table 5.Household Transmission Analysis


Household	Transmission Direction	SNV Distance	Difference in Dates of Diagnosis (Days)	iSNV Information	Transmission Pair Categorization	Household Transmission Categorization
JRP	1>2	1	4		Highly probable	Highly probable
EGI	1>4	1	4		Highly probable	Highly probable
CWA	1>2	0	2	C21721T; T22917A; C23673T present at mixed sites in 1 (possible	Possible	
CWA	2>1	0	-2	BA.2.12.1 & BA.2.10 co-infection) and fixed in 2	Possible	Possible
TSE	1>2	3	5		Unlikely	Unlikoly
ISE	2>1	3	-5		Unlikely	– Unlikely
DUC	1>2	0	2		Possible	Possible
DUC	2>1	0	-2		Possible	Possible
	4>2	0	3		Possible	Possible
МРО	4>3	0	6		Possible	
MPO	2>4	0	-3		Possible	
	2>3	0	3		Possible	
IIVI	1>3	0	1	share $C^{2202T}$ at $< 100$ for such as	Possible	Possible
HXJ	3>1	0	-1	share C23393T at < 10% frequency	Possible	Possible
DOE	2>1	0	2		Possible	Possible
BQE	1>2	0	-2		Possible	Possible
	1>4	3	2		Unlikely	 Mixed household
	4>1	3	-2		Unlikely	
IRG	4>2	0	3		Possible	
	4>3	0	5		Possible	
	2>3	0	2		Possible	
LCT	4>1	4	1		Unlikely	Mixed household


	1>4	4	-1		Unlikely	
	4>5	0	5		Possible	
PFK	1>4	0	6		Highly probable	Possible
XOA	1>2	13	9	share C3832T at < 10% frequency	Unlikely	Unlikely
WMD	1>3	20	12		Unlikely	Unlikely
HSA	1>2	2	5		Highly probable	Possible
	1>2	0	2		Possible	
	1>4	0	2		Possible	
OXS	2>1	0	-2		Possible	
UAS	2>4	0	0		Possible	Possible
	4>1	0	-2		Possible	
	4>2	0	0		Possible	





В





## **SUPPLEMENTAL FIGURE 1**

